* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Sunday, June 22, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Netflix unveils Dallas immersive venue for fans of hit shows like ‘Squid Game,’ ‘Stranger Things’ – Houston Chronicle

    Step Inside Netflix’s New Dallas Immersive Experience Featuring Hits Like ‘Squid Game’ and ‘Stranger Things

    ‘Puttin’ on the Ritz’: Civic Players bring ‘Young Frankenstein’ to life – Yahoo

    Civic Players Deliver a Hilarious and Unforgettable Performance of ‘Young Frankenstein

    ‘Wheel of Fortune’: Amputee Wins $60,000 After Breaking Incredible ‘Curse’ – Hastings Tribune

    Wheel of Fortune’ Amputee Breaks Incredible ‘Curse’ to Win $60,000!

    North Star Sports & Entertainment Network: Coming soon – KTTC News

    North Star Sports & Entertainment Network: Coming soon – KTTC News

    Safety concerns in Deep Ellum create apprehension as the entertainment district gains visitors – CBS News

    Safety Concerns Surge Amid Deep Ellum’s Booming Popularity and Growing Crowds

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Tech Champions with Leo Bletnitsky of Healthy Technology Solutions – Buzz Media Group

    Meet Tech Champion Leo Bletnitsky of Healthy Technology Solutions

    Crypto’s true revolution is about humanity, not technology – Cointelegraph

    Crypto’s Real Revolution: Transforming Humanity Beyond Technology

    $1 Billion Problem: New Technology Could Save Your Daily Cup of Coffee – SciTechDaily

    The $1 Billion Challenge: How New Technology Could Rescue Your Daily Cup of Coffee

    Canada’s construction industry gets serious about investing in technology as pressure mounts to do more with less – Yahoo Finance

    Canada’s Construction Industry Accelerates Tech Investments to Overcome Growing Challenges and Boost Efficiency

    Workforce Technology Eases Staffing Shortages in Rural Health Care – AJMC

    Workforce Technology Eases Staffing Shortages in Rural Health Care – AJMC

    Get the lead out: Putting new at-home lead testing technology to the test | Denver7 Investigates – Denver7

    Putting the Latest At-Home Lead Testing Technology to the Ultimate Test

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Netflix unveils Dallas immersive venue for fans of hit shows like ‘Squid Game,’ ‘Stranger Things’ – Houston Chronicle

    Step Inside Netflix’s New Dallas Immersive Experience Featuring Hits Like ‘Squid Game’ and ‘Stranger Things

    ‘Puttin’ on the Ritz’: Civic Players bring ‘Young Frankenstein’ to life – Yahoo

    Civic Players Deliver a Hilarious and Unforgettable Performance of ‘Young Frankenstein

    ‘Wheel of Fortune’: Amputee Wins $60,000 After Breaking Incredible ‘Curse’ – Hastings Tribune

    Wheel of Fortune’ Amputee Breaks Incredible ‘Curse’ to Win $60,000!

    North Star Sports & Entertainment Network: Coming soon – KTTC News

    North Star Sports & Entertainment Network: Coming soon – KTTC News

    Safety concerns in Deep Ellum create apprehension as the entertainment district gains visitors – CBS News

    Safety Concerns Surge Amid Deep Ellum’s Booming Popularity and Growing Crowds

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Tech Champions with Leo Bletnitsky of Healthy Technology Solutions – Buzz Media Group

    Meet Tech Champion Leo Bletnitsky of Healthy Technology Solutions

    Crypto’s true revolution is about humanity, not technology – Cointelegraph

    Crypto’s Real Revolution: Transforming Humanity Beyond Technology

    $1 Billion Problem: New Technology Could Save Your Daily Cup of Coffee – SciTechDaily

    The $1 Billion Challenge: How New Technology Could Rescue Your Daily Cup of Coffee

    Canada’s construction industry gets serious about investing in technology as pressure mounts to do more with less – Yahoo Finance

    Canada’s Construction Industry Accelerates Tech Investments to Overcome Growing Challenges and Boost Efficiency

    Workforce Technology Eases Staffing Shortages in Rural Health Care – AJMC

    Workforce Technology Eases Staffing Shortages in Rural Health Care – AJMC

    Get the lead out: Putting new at-home lead testing technology to the test | Denver7 Investigates – Denver7

    Putting the Latest At-Home Lead Testing Technology to the Ultimate Test

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Second-Line CAR-T Improves Survival in Large B-Cell Lymphoma

June 22, 2023
in Health
Second-Line CAR-T Improves Survival in Large B-Cell Lymphoma
Share on FacebookShare on Twitter

Treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) resulted in significantly improved overall survival compared with the current standard of care among patients with early relapsed or refractory large B-cell lymphoma (LBCL), according to findings from the phase III ZUMA-7 trial, which were presented at the American Society of Clinical Oncology (ASCO) annual meeting and published concurrently in the New England Journal of Medicine.

MedPage Today brought together three expert leaders in the field: Moderator Ian Flinn, MD, PhD, from the Sarah Cannon Research Institute in Nashville, Tennessee, is joined by Caron A. Jacobson, MD, from the Dana-Farber Cancer Institute in Boston, and Jason Westin, MD, from the University of Texas MD Anderson Cancer Center in Houston, for a virtual roundtable discussion. This second of four exclusive episodes focuses on the overall survival data from the ZUMA-7 trial.

Following is a transcript of their remarks:

Flinn: Jason, you presented data on ZUMA-7, and of course this was groundbreaking news when it was first presented, showing a significant improvement in progression-free survival for those patients who received the axi-cel CAR-T compared to the standard of care. But you presented data on overall survival. Maybe you could walk us through that and your thoughts on it.

Westin: Absolutely, and Dr. Jacobson’s a treasured collaborator on that study and a co-author on the manuscript that was published, so giving her her due on this as well. But the update we presented at the ASCO 2023 meeting for ZUMA-7 is that we now have a statistically significant improvement in overall survival in second line. And that’s the first time in nearly 30 years since the Parma trial that showed that transplant was significantly improved over chemotherapy. It’s the first time we’ve shown that statistically significant improvement in overall survival.

So axi-cel had a hazard ratio of 0.726, with a statistically significant P value, despite the fact that a little bit more than half of the patients, 57% of the patients on the standard-of-care arm, actually received subsequent cellular immunotherapy, which was largely CAR T-cell therapy in the third- or later-line setting.

So with that effective strategy of try chemo first, save CAR T cell for later, we can now say that using second line axi-cel is superior to that approach. And I think that this, in my opinion at least, ends the debate about, is trying chemo to see if the patient responds and saving CAR T cell for a later day, I think that ends the debate and says that second-line CAR T cells are superior to the prior paradigm.

Flinn: I think it really must, I mean that, you’re right, there was a debate after the original presentations and even including the BELINDA data, which seemed to me answered that question. I mean, there was such a long delay and people got third-line therapy.

Caron, as Jason was saying, you’re an investigator on this trial and what sort of strategies have you adopted in your practice in order to get patients into the clinic early and to avoid some of the delays and the need for third-line therapy?

Jacobson: Yeah, this is a really important aspect of this approval in the second line because when patients were getting CAR T cell in the third line, we had a natural referral pattern, which was send patients in at the time of relapse. While you’re waiting to see if they respond to second-line chemotherapy, you could then encourage them based on their response to CAR-T versus auto transplant.

Now we have patients and we’re seeing a very high percentage of patients coming in with primary refractory disease with very rapidly progressive tumors and large burdens of disease. And it’s actually really challenging to get them in to be seen as an initial consult, get them insurance approval, and get the ball rolling for their CAR T cells, not to mention the time it takes to manufacture the CAR T cells.

So, in practice, what is happening is oftentimes there’s a phone consultation with the referring doctor to discuss the patient and even potentially get the patient started on some sort of pre-bridging therapy before they even come to see you in clinic. And then with a plan to give them a subsequent cycle of bridging therapy following T-cell collection.

I think that we have to think about a shift in our referral practice because of this approval. I think the high-risk patients in the frontline should come in during their initial chemoimmunotherapy. So patients with high IPIs [International Prognostic Index], patients with high-grade B-cell lymphoma, double-hit lymphomas, they should come into CAR T-cell treatment centers just for an initial consult, so that they’re already known to us, which makes it much, much easier to feed them into the CAR-T pipeline if and when they’re either primary refractory or early relapsing.

Flinn: You know, that sounds like a great strategy. So we’ve seen CAR T cells move from third line to second line, and then I know, Jason we’ll return to you, there’s now an effort to try to move them into frontline, right? For a high-risk patient population. Some of the questions around that, it’s like, how do you define a high-risk grouping that you would justify use of CAR T cells in? And maybe you could speak to, there’s currently a trial, I think it’s ZUMA-23, looking at this.

Westin: That’s exactly right. So we had a trial-in-progress poster at the ASCO meeting for ZUMA-23. Dr. Jacobson’s involved in that trial as well. And that is for frontline patients that have an IPI of 4 or 5. And so that’s how we’re defining it for that study, it’s just the highest-risk patients, IPI 4-5. And just like Dr. Jacobson just said for the second line, that’s a group that sometimes is difficult to enroll into trials because if their performance status is limited by definition of having an IPI of 5, that’s a group that’s historically underrepresented on clinical studies.

Also, these patients are often the ones that show up in your clinic and need to be admitted to the hospital to start chemotherapy in the next couple of days. They don’t often wait very well for review of eligibility or financial clearance or the other things that we put up as unintentional barriers to get the sickest patients onto our studies.

So this trial actually accounts for that by mandating patients to have one cycle of R [rituximab] chemotherapy prior to being eligible for the trial. So all patients going on the ZUMA-23 trial have that high IPI diagnosis and then get one cycle of R chemo and it’s agnostic as to what that one cycle is. And then they can be enrolled on the trial and randomized 1:1 either to receive standard chemotherapy, basically stay the course and finish out your planned six cycles of either R-CHOP or R-EPOCH, or to be randomized to the axi-cel arm where they’d undergo apheresis, get a second cycle of R chemo as effectively a bridge to keep the Q3-week intensity of therapy ongoing and then get axi-cel and then they’re done.

And this is a large phase III global trial up and running now to basically ask, can CAR T cell supplant frontline chemotherapy in that ultra-high-risk patient population?

Flinn: I mean, it will certainly be interesting to see the outcomes here, but I guess as we move earlier in the course of disease, that it does get hard statistically to have some of these positive outcomes, although clearly this is a rich population for that to happen.

Watch episode one: Including Polatuzumab Vedotin in First-Line DLBCL Treatment

author['full_name']

Greg Laub is the Senior Director of Video and currently leads the video and podcast production teams. Follow

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/ascoexpertroundtabledlbcl/105130

Tags: CAR-ThealthSecond-Line
Previous Post

Rates of Consent Withdrawal in Cancer Trials Low but Not ‘Trivial’

Next Post

Monarch butterflies’ big white spots help them fly better

When Technology Meets Ecology: Charting a Bold Path for Our Planet’s Future

June 21, 2025
‘Jaws’ at 50: Scientists Are Still Studying the Mysteries of Sharks – The New York Times

Jaws at 50: Exploring the Timeless Mysteries of Sharks

June 21, 2025
A Cracked Piece of Metal Self-Healed in Experiment That Stunned Scientists – ScienceAlert

Self-Healing Metal: The Revolutionary Experiment That Amazed Scientists

June 21, 2025
How leading Bollywood actresses are adopting one transformative lifestyle shift – Times of India

How Leading Bollywood Actresses Are Fearlessly Embracing a Bold New Lifestyle Transformation

June 21, 2025
Muskego mom breaks world record in planking – WISN

Muskego mom breaks world record in planking – WISN

June 21, 2025
Russian Minister Warns of Recession as Officials Spar on Economy – Bloomberg

Russian Minister Issues Recession Warning Amid Heated Economic Debate

June 21, 2025
Netflix unveils Dallas immersive venue for fans of hit shows like ‘Squid Game,’ ‘Stranger Things’ – Houston Chronicle

Step Inside Netflix’s New Dallas Immersive Experience Featuring Hits Like ‘Squid Game’ and ‘Stranger Things

June 21, 2025
Breakfast key to meeting daily fiber needs amid American ‘health crisis’ – Fox News

How Breakfast Can Help You Crush Your Daily Fiber Goals During America’s Health Crisis

June 21, 2025
A Senator Who Was on a Hit List Fears the Fueling of Political Violence – The New York Times

Senator on Hit List Sounds Alarm Over Escalating Political Violence

June 21, 2025
Should You Buy Micron Technology Stock Before June 25? – The Motley Fool

Is Now the Perfect Moment to Invest in Micron Technology Before June 25?

June 21, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (696)
  • Economy (710)
  • Entertainment (21,611)
  • General (15,499)
  • Health (9,751)
  • Lifestyle (715)
  • News (22,149)
  • People (713)
  • Politics (717)
  • Science (15,930)
  • Sports (21,206)
  • Technology (15,695)
  • World (690)

Recent News

When Technology Meets Ecology: Charting a Bold Path for Our Planet’s Future

June 21, 2025
‘Jaws’ at 50: Scientists Are Still Studying the Mysteries of Sharks – The New York Times

Jaws at 50: Exploring the Timeless Mysteries of Sharks

June 21, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version